| 注册
首页|期刊导航|解放军医学院学报|PD-1抑制剂联合化疗治疗复发性宫颈癌的有效性及安全性临床研究

PD-1抑制剂联合化疗治疗复发性宫颈癌的有效性及安全性临床研究

郝俊宽 李立安 王政 王楠 孟元光

解放军医学院学报2025,Vol.46Issue(5):449-454,475,7.
解放军医学院学报2025,Vol.46Issue(5):449-454,475,7.DOI:10.12435/j.issn.2095-5227.2025.24093002

PD-1抑制剂联合化疗治疗复发性宫颈癌的有效性及安全性临床研究

Clinical outcomes and safety of PD-1 inhibitors in combination with chemotherapy in patients with recurrent cervical cancer

郝俊宽 1李立安 2王政 3王楠 2孟元光2

作者信息

  • 1. 解放军医学院,北京 100853
  • 2. 解放军总医院第一医学中心妇产科,北京 100853
  • 3. 南开大学医学院,天津 300071
  • 折叠

摘要

Abstract

Background Clinical trials have shown that the combination of PD-1 inhibitors and chemotherapy is effective in treating recurrent cervical cancer(rCC),but there are relatively few real-world studies on the combination of PD-1 inhibitors and chemotherapy for rCC.Objective To explore the actual clinical effects of PD-1 inhibitors combined with chemotherapy in rCC patients.Methods Patients with rCC who received PD-1 inhibitors with chemotherapy in the First Medical Center of Chinese PLA General Hospital from July 2014 to July 2022 were served as the observation group,and rCC patients who received the same chemotherapy regimen during the same period as the control group.The objective response rate(ORR),disease control rate(DCR),median overall survival(mOS),1-year survival rate,2-year survival rate,and the degree of decline in squamous cell carcinoma antigen(SCCAg)in patients with squamous cell carcinoma and adverse reactions were compared between the two groups.Results A total of 88 patients were enrolled in the study,with 39 cases in the observation group and 49 cases in the control group.The general information and clinical baseline data of the two groups were comparable(P>0.05).The ORR of the observation group was higher than that of the control group(59.0%vs 32.7%,P=0.014),while the DCR showed no significant difference between the two groups(89.7%vs 83.7%,P=0.410).The mOS in the observation group was 16.0 months(95%CI:13.66-39.70),which was higher than the 15.0 months(95%CI:12.70-18.58)in the control group,but the difference was not statistically significant(P=0.176).The 1-year survival rate of the observation group was higher than that of the control group(84.6%vs 67.3%,P=0.047),and the 2-year survival rate was also higher than that of the control group(69.2%vs 46.9%,P=0.024).For patients with squamous cell carcinoma,compared with before treatment,the sera SCCAg level decreased after treatment in the observation group(P<0.001),and the SCCAg level in the observation group was lower than that in the control group after treatment(P=0.046).There was no significant difference in the main adverse reactions between the two groups(P>0.05).The incidence of myelosuppression in the observation group was higher than that in the control group(92.3%vs 71.4%,P=0.014),but there was no difference in severe Ⅲ-Ⅳ degree myelosuppression(20.5%vs 16.3%,P=0.613).Conclusion PD-1 inhibitors combined with chemotherapy are more effective in controlling the progression of rCC than chemotherapy alone.Although the incidence of myelosuppression is higher,it does not increase the incidence of severe myelosuppression,and the safety is controllable.

关键词

复发性宫颈癌/PD-1抑制剂/化疗/有效性/不良反应

Key words

recurrent cervical cancer/PD-1 inhibitors/chemotherapy/effectiveness/adverse effects

分类

医药卫生

引用本文复制引用

郝俊宽,李立安,王政,王楠,孟元光..PD-1抑制剂联合化疗治疗复发性宫颈癌的有效性及安全性临床研究[J].解放军医学院学报,2025,46(5):449-454,475,7.

解放军医学院学报

2095-5227

访问量0
|
下载量0
段落导航相关论文